JP2013504593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504593A5 JP2013504593A5 JP2012528926A JP2012528926A JP2013504593A5 JP 2013504593 A5 JP2013504593 A5 JP 2013504593A5 JP 2012528926 A JP2012528926 A JP 2012528926A JP 2012528926 A JP2012528926 A JP 2012528926A JP 2013504593 A5 JP2013504593 A5 JP 2013504593A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- heteroalkyl
- alkyl
- carbocyclyl
- heterocyclylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 127
- 125000000623 heterocyclic group Chemical group 0.000 claims description 103
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 86
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 80
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 78
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 76
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 70
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 60
- 125000001188 haloalkyl group Chemical group 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000002947 alkylene group Chemical group 0.000 claims description 40
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 40
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 40
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 40
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 36
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 34
- 125000003107 substituted aryl group Chemical group 0.000 claims description 29
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 22
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004419 alkynylene group Chemical group 0.000 claims description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 108020000999 Viral RNA Proteins 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 125000005549 heteroarylene group Chemical group 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- -1 -OH Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000003627 8 membered carbocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24219409P | 2009-09-14 | 2009-09-14 | |
| US61/242,194 | 2009-09-14 | ||
| PCT/US2010/048424 WO2011031965A1 (en) | 2009-09-14 | 2010-09-10 | Modulators of toll-like receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504593A JP2013504593A (ja) | 2013-02-07 |
| JP2013504593A5 true JP2013504593A5 (https=) | 2013-10-31 |
| JP5763077B2 JP5763077B2 (ja) | 2015-08-12 |
Family
ID=43332257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528926A Active JP5763077B2 (ja) | 2009-09-14 | 2010-09-10 | トール様受容体のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8476270B2 (https=) |
| EP (1) | EP2477987B1 (https=) |
| JP (1) | JP5763077B2 (https=) |
| AU (1) | AU2010292102B2 (https=) |
| CA (1) | CA2772253C (https=) |
| ES (1) | ES2661850T3 (https=) |
| NO (1) | NO2477987T3 (https=) |
| NZ (1) | NZ598384A (https=) |
| PL (1) | PL2477987T3 (https=) |
| PT (1) | PT2477987T (https=) |
| SI (1) | SI2477987T1 (https=) |
| WO (1) | WO2011031965A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| CA2788678C (en) | 2010-02-03 | 2019-02-26 | Signal Pharmaceuticals, Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| JP2014525932A (ja) | 2011-08-15 | 2014-10-02 | インターミューン， インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN105377299B (zh) | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| KR102306860B1 (ko) * | 2014-09-16 | 2021-09-30 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체 조정제를 제조하는 방법 |
| SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| WO2018095426A1 (zh) | 2016-11-28 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN109937205B (zh) * | 2017-01-24 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 杂芳基并噻二嗪-2,2-二氧化物类衍生物、其制备方法及其在医药上的应用 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP2020520379A (ja) | 2017-05-18 | 2020-07-09 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用 |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| MX2020012651A (es) | 2018-05-25 | 2021-02-02 | Jiangsu Hengrui Medicine Co | Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion. |
| AU2019272478B2 (en) | 2018-05-25 | 2024-06-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| KR102514860B1 (ko) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US29885A (en) * | 1860-09-04 | Improvement in harrows | ||
| US263470A (en) * | 1882-08-29 | Grate for boiler-furnaces | ||
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA2017507C (en) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JP2886570B2 (ja) | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| TW274550B (https=) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| EP0743855A1 (en) * | 1994-01-03 | 1996-11-27 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| BR9710808A (pt) | 1996-08-06 | 1999-08-17 | Pfizer | Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos |
| US5693641A (en) * | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO2000000478A1 (en) | 1998-06-26 | 2000-01-06 | Bristol-Myers Squibb Pharma Company | Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
| US7169778B2 (en) | 1999-09-15 | 2007-01-30 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| US6452325B1 (en) * | 2000-07-24 | 2002-09-17 | Thermoplastic Processes, Inc. | Shatterproofing of fluorescent lamps |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| UA76512C2 (en) | 2001-09-04 | 2006-08-15 | Boehringer Ingelheim Pharma | Dihydropteridinones, a method for producing thereof and use thereof as medicament |
| JP3876265B2 (ja) | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| EP2269638A3 (en) | 2004-05-28 | 2012-06-13 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| AU2006242920A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C |
| CA2617589A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| JP2009528989A (ja) * | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| EP2004193A2 (en) | 2006-03-13 | 2008-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP2009541284A (ja) | 2006-06-23 | 2009-11-26 | アストラゼネカ・アクチエボラーグ | プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用 |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| AR065372A1 (es) | 2007-02-19 | 2009-06-03 | Smithkline Beecham Corp | Derivados de purina |
| AU2008228303B2 (en) | 2007-03-22 | 2012-04-19 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as PLK1 inhibitors |
| HRP20120895T1 (hr) * | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| CA2691444C (en) * | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| ES2359123T3 (es) * | 2007-08-03 | 2011-05-18 | Pfizer Limited | Imidazopiridinonas. |
| AU2008287339A1 (en) | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| WO2009022185A2 (en) | 2007-08-16 | 2009-02-19 | Astrazeneca Ab | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
| US20090291938A1 (en) | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| RS53347B (sr) * | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
-
2010
- 2010-09-10 CA CA2772253A patent/CA2772253C/en active Active
- 2010-09-10 PL PL10760831T patent/PL2477987T3/pl unknown
- 2010-09-10 US US12/879,697 patent/US8476270B2/en active Active
- 2010-09-10 NZ NZ598384A patent/NZ598384A/en not_active IP Right Cessation
- 2010-09-10 AU AU2010292102A patent/AU2010292102B2/en active Active
- 2010-09-10 WO PCT/US2010/048424 patent/WO2011031965A1/en not_active Ceased
- 2010-09-10 EP EP10760831.7A patent/EP2477987B1/en active Active
- 2010-09-10 PT PT107608317T patent/PT2477987T/pt unknown
- 2010-09-10 NO NO10760831A patent/NO2477987T3/no unknown
- 2010-09-10 JP JP2012528926A patent/JP5763077B2/ja active Active
- 2010-09-10 ES ES10760831.7T patent/ES2661850T3/es active Active
- 2010-09-10 SI SI201031640T patent/SI2477987T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504593A5 (https=) | ||
| JP2013508373A5 (https=) | ||
| JP2012517444A5 (https=) | ||
| JP2013538230A5 (https=) | ||
| JP2012530713A5 (https=) | ||
| JP2017533968A5 (https=) | ||
| JP2019529490A5 (https=) | ||
| JP2020521741A5 (https=) | ||
| JP2011522789A5 (https=) | ||
| JP2012504608A5 (https=) | ||
| RU2012116526A (ru) | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы | |
| JP2012528166A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2011521911A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2007502288A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2011523411A5 (https=) | ||
| JP2011520906A5 (https=) | ||
| JP2011515483A5 (https=) | ||
| JP2009534358A5 (https=) | ||
| JP2010524932A5 (https=) | ||
| JP2013544261A5 (https=) | ||
| JP2008535903A5 (https=) |